IPF Ofev denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for ipf ofev are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Apply Quantity Limits to Ofev (nintedanib) for IPF

Cigna's quantity-limit edits for Ofev restrict the number of units that will be dispensed per fill or per coverage period to what the plan considers consistent with standard prescribing patterns. Quantity-limit denials for Ofev typically occur when the prescription is written at a dosing regimen or supply quantity that the plan's system flags as outside its default parameters — for example, a 90-day supply when the policy limit is 30 days, or a dispensed quantity that reflects a dose adjustment not yet reflected in the plan's criteria. The plan is not necessarily denying the drug; it is limiting how much will be covered at one time.

## Why This Denial Is Appealable

Quantity limits are a plan-administrative tool, not a clinical judgment about your individual care. When the prescribed quantity is supported by the FDA-approved prescribing label and by the prescriber's documented clinical rationale — including any dose adjustment and its basis — the plan must justify why its administrative limit overrides the individualized prescription. These appeals succeed regularly when the prescriber provides a clear explanation.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your Explanation of Benefits. Cigna must decide within 30 days (non-urgent) or 72 hours (expedited).
• Exception request: Many plans have a separate quantity-limit exception pathway; ask Cigna or your prescriber's office whether this runs parallel to or instead of a formal appeal.
• External review (ACA §2719): After an adverse internal decision, request independent external review. The reviewer will assess whether the quantity limit as applied to your case is clinically supportable. The window is generally up to four months from the denial notice.
• ERISA §503: Employer-plan members have federal full-and-fair review rights.
• Expedited review: Available if your prescriber certifies that the standard timeline jeopardizes your health.

## Documentation to Gather

1. Current FDA-approved prescribing label — The prescriber letter should reference the prescribing label to confirm that the prescribed quantity and dosing regimen are within label parameters. Direct Cigna to the label for exact dosing guidance. 2. Prescriber medical-necessity letter — Explains the prescribed dose, the clinical basis for any individualized dosing decision, and why the requested quantity is appropriate for this patient's care plan. 3. Diagnosis and disease severity documentation — Specialist records confirming IPF diagnosis and current clinical status that inform the dosing decision. 4. Pharmacy fill history — If a prior quantity was approved and this refill is being limited, a fill history shows continuity of therapy and the prior approved quantity. 5. Dose adjustment rationale — If the prescription reflects a dose change, the prescriber should document the clinical reason for the adjustment (e.g., tolerability, disease progression) without citing specific numbers that could conflict with the insurer's criteria.

## Criteria-Mapping Structure

Obtain Cigna's published quantity-limit policy for Ofev. For each stated criterion:

• Prescribed quantity consistent with FDA-approved dosing parameters — reference the prescribing label
• Clinical rationale for the specific quantity prescribed — prescriber letter
• Diagnosis and disease severity supporting the treatment duration requested — specialist records
• Prior authorization status confirming the drug itself is approved for this patient

The most efficient appeal pairs a brief prescriber letter citing the FDA label's dosing range with the specialist's current chart note confirming disease status.